Showing 931-940 of 1211 results for "".
- AHA Presses for Changes to COVID-19 Vaccine Rollout and for HHS to Take Larger Rolehttps://modernod.com/news/aha-presses-for-changes-to-covid-19-vaccine-rollout-and-for-hhs-to-take-larger-role/2478736/The American Hospital Association is imploring the Trump administration to make several moves aimed at improving the disparate rollout of COVID-19 vaccines, which in some cases has overwhelmed facilities, according to a FierceHealthcare
- Prediabetes Linked to Macular Thinninghttps://modernod.com/news/prediabetes-linked-to-macular-thinning/2478592/Prediabetes is associated with significant thinning of the macula and with decreases in retinal-artery diameters, according to a population-based study. Various retinal changes have been reported in individuals with impaired fasting glucose or hyperglycemia, but it remains unclear whether
- FDA Grants Orphan Drug Designation for Neurophth Therapeutics’ Gene Therapy for LHONhttps://modernod.com/news/fda-grants-orphan-drug-designation-for-neurophth-therapeutics-gene-therapy-for-lhon/2478326/Neurophth Therapeutics announced that its leading candidate, NR082, was granted an orphan drug designation (ODD) by the FDA for the treatment of Leber’s Hereditary Optic Neuropathy (LHON) associated with ND4 mutation. LHON is a maternall
- Liminal BioSciences Provides Update on Progress on BLA for Ryplazim (Plasminogen)https://modernod.com/news/liminal-biosciences-provides-update-on-progress-on-bla-for-ryplazim-plasminogen/2478301/Liminal BioSciences announced that the FDA acknowledged receipt of the resubmission of the Biologic License Application (BLA) for Ryplazim (plasminogen) for the treatment of clinical signs and symptoms associated with congenital plasminogen deficiency (C-PLGD) in pediatrics and adults. The
- Nicox Partners Zerviate in the Gulf and Arab Marketshttps://modernod.com/news/nicox-partners-zerviate-in-the-gulf-and-arab-markets/2478152/Nicox SA announced the signature of an exclusive license agreement with Itrom Pharmaceutical Group for the registration and commercialization of Zerviate (cetirizine ophthalmic solution), 0.24% for the treatment of ocular itching associated with allergic conjunctivitis in Gulf and Arab markets. I
- Pepcid As a Coronavirus Remedy? Trump’s $21-Million Gamble Fizzledhttps://modernod.com/news/pepcid-as-a-coronavirus-remedy-trumps-21-million-gamble-fizzled/2478070/As the coronavirus began its deadly march through the world, two well-respected American doctors identified a possible but seemingly unlikely remedy: Pepcid, the heartburn medication found on drugstore shelves everywhere, according to an Associated
- AORN Releases Survey Results Exploring ORs’ Return to Pre-COVID-19 Surgical Volumeshttps://modernod.com/news/aorn-releases-survey-results-exploring-ors-return-to-pre-covid-19-surgical-volumes/2479521/The Association of periOperative Registered Nurses (AORN) announced survey results of more than 1,000 surgical nurse leaders in the United States regarding how their facilities are managing the resumption of elective surgeries. Key Findings The top three spec
- The Lancet Withdraws Major Hydroxychloroquine Studyhttps://modernod.com/news/the-lancet-withdraws-controversial-hydroxychloroquine-study/2477866/A major study in the Lancet that suggested hydroxychloroquine was associated with higher rates of ventricular arrhythmia and death in COVID-19 patients has been retracted. The multinational registry analysis, published in the Lancet on May 22, included nearly 15,000 peopl
- AMA Issues Guidance to Physicians on Using COVID-19 Antibody Testshttps://modernod.com/news/ama-issues-guidance-to-physicians-on-using-covid-19-antibody-tests/2477783/As new serology tests for COVID-19 rapidly come to the market, the American Medical Association (AMA) is cautioning physicians about using these tests to make healthcare decisions for individual patients, according to a FierceHealthcare
- InMed Files PCT Patent Application for Neuroprotection in Glaucomahttps://modernod.com/news/inmed-files-pct-patent-application-for-neuroprotection-in-glaucoma/2477748/InMed Pharmaceuticals announced that it has filed a Patent Cooperation Treaty (PCT) application pertaining to the potential of cannabinoids in the prevention of neuron damage associated with glaucoma. The patent application, entitled “Compositions and Methods for Use of Cannabinoids